<DOC>
	<DOCNO>NCT01814722</DOCNO>
	<brief_summary>This multi-center , longitudinal observational study adult human immunodeficiency virus ( HIV ) participant academic community-based practice United States switch first-line second-line therapy . The study 's primary hypothesis HIV participant switch raltegravir-based regimen well Medical Outcomes Study-HIV ( MOS-HIV ) Health Survey score participant switch non-nucleoside reverse transcriptase inhibitor ( NNRTI ) -based protease inhibitor ( PI ) -based regimen .</brief_summary>
	<brief_title>Quality Life HIV-infected Participants Switched Raltegravir Versus Other Antiretroviral Regimens ( MK-0518-266 )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Clinical diagnosis HIV Switching antiretroviral regimen ( ) first time start study Currently pregnant Presence active tuberculosis , Hepatitis B , and/or Hepatitis C receive treatment condition ( ) study period Presence active pneumonia sign opportunistic infection start study Currently participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Anti-Retroviral Agents</keyword>
	<keyword>Nucleoside Reverse Transcriptase Inhibitors</keyword>
	<keyword>Non-nucleoside Reverse Transcriptase Inhibitor</keyword>
	<keyword>Protease inhibitor</keyword>
</DOC>